According to reports, Swedish health authorities have decided to impose an indefinite suspension on administering the Moderna vaccination to anybody under the age of 31. The Moderna shots were originally supposed to be resumed on December 1st.
In the case of the Moderna vaccination, Finland, Iceland, and Denmark have taken comparable measures to Sweden. Norway encourages males under 30 to avoid the Moderna vaccine, but the country hasn’t gone so far as to outright prohibit the act.
The Moderna vaccine has been under fire for months due to studies showing that young men who take it are more likely to develop myocarditis, a condition of the heart that causes muscle inflammation, and pericarditis, an inflammation of the sac surrounding the heart.
Moderna’s intentions for the jab targeting the population aged 12 to 17 have been put on hold by the U.S. Food and Drug Administration owing to worries about the adverse effects of the vaccine.
While a panel from the Centers for Disease Control and Prevention had authorized boosters for the Moderna and Johnson & Johnson vaccines on October 21st, certain concerns were expressed.
According to Dr. Tom Shimabukuro, both the Moderna and Pfizer vaccinations increase the risk of myocarditis and pericarditis, especially after the second dosage. But the two shots aren’t exactly the same in terms of the risk of the aforementioned.
According to data, people who have received the Moderna vaccination faced a 13-fold higher risk than those who received the Pfizer vaccine.
Sweden’s Public Health Agency said of the unpublished data linking the Moderna vaccine to myocarditis and pericarditis that there’s “an increased risk of side effects such as inflammation of the heart muscle or the pericardium.”
With respect to the Pfizer vaccine, the FDA also addressed risks related to myocarditis and pericarditis while announcing the vaccine’s FDA approval back in August:
“Additionally, the FDA conducted a rigorous evaluation of the post-authorization safety surveillance data pertaining to myocarditis and pericarditis following administration of the Pfizer-BioNTech COVID-19 Vaccine and has determined that the data demonstrate increased risks, particularly within the seven days following the second dose.
The observed risk is higher among males under 40 years of age compared to females and older males. The observed risk is highest in males 12 through 17 years of age. Available data from short-term follow-up suggest that most individuals have had resolution of symptoms. However, some individuals required intensive care support.”